Summary
In this joint webinar with Sanofi, we discuss an approach that combines mechanistic modeling with machine learning, to obtain deeper insights and guide therapeutic strategies, for inflammatory bowel disease (IBD).
We begin our webinar with an introduction to QSP, followed by an overview of the virtual patient technology and its application in inflammatory bowel disease (IBD). Our speakers will share a case study to further elucidate applications. And finally, we will have an overall discussion of the impact this approach can have on drug development decision-making. At the end of the webinar, our expert speakers take questions from you.
Key Learning Objectives:
- Familiarize yourself with the current fast-changing landscape and trends in Quantitative Systems Pharmacology (QSP) and its applications in inflammatory bowel disease (IBD)
- Get an overview of the virtual patient technology and applications, followed by a case study
- Learn about the impact of this approach on drug development decision-making
お申込みはこちら
Senior Vice President, Head of QSP
Piet van der Graafはサターラの上級副社長兼定量システム薬理学部長で、ライデン大学のシステム薬理学教授。2013年から2016年までライデン薬学アカデミックセンターの研究部長を務めました。From 1999-2013 he held various leadership positions at Pfizer in Discovery Biology, Pharmacokinetics and Drug Metabolism and Clinical Pharmacology. He was the founding Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology from 2012-2018 before becoming Editor-in-Chief of Clinical Pharmacology & Therapeutics. Piet received his doctorate training in clinical medicine with Nobel prize laureate Sir James Black at King’s College London. He has been awarded the 2024 Gary Neil Prize for Innovation in Drug Development from the American Society of Clinical Pharmacology and Therapeutics (ASCPT) and was the recipient of the 2021 Leadership Award from the International Society of Pharmacometrics (ISoP). Piet is an elected Fellow of the British Pharmacological Society and has published >200 articles in the area of quantitative pharmacology and drug development.
Sr Director, QSP
Douglas W. Chung is a highly experienced scientist and consultant specializing in mechanistic modeling to support drug discovery and development. His background is in biomedical engineering and his focus is in quantitative systems pharmacology with over 12 years of experience consulting in biotech and pharmaceuticals. His passion is to grow the field of quantitative pharmacology by expanding diversity in people, fields of expertise, and clinical trial populations.
Head of QSP Germany, Sanofi
As Head of Quantitative Systems Pharmacology Germany, Britta oversees QSP projects and quantitative pharmacology strategy. She advances virtual patient engines and in-silico clinical trials to impact drug research and development, improve portfolio decisions, increase probability of success, and accelerate development of innovative medication for patients, improving people’s lives. With more than 10 years of experience in the pharmaceutical industry, she brings remarkable expertise and proven track record of delivering high value modeling & simulation solutions for diverse modalities across therapeutic areas including immunology & inflammation and metabolism. Britta holds a PhD in Computational Life Science from Luebeck University.
Associate Director of QSP, Sanofi
お申込みはこちら
